Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK-1654 in Healthy Adults.
Aliprantis AO, Wolford D, Caro L, Maas BM, Ma H, Montgomery DL, Sterling LM, Hunt A, Cox KS, Vora KA, Roadcap BA, Railkar RA, Lee AW, Stoch SA, Lai E. Aliprantis AO, et al. Among authors: maas bm. Clin Pharmacol Drug Dev. 2021 May;10(5):556-566. doi: 10.1002/cpdd.883. Epub 2020 Oct 30. Clin Pharmacol Drug Dev. 2021. PMID: 33125189 Clinical Trial.
Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis.
Maas BM, Lommerse J, Plock N, Railkar RA, Cheung SYA, Caro L, Chen J, Liu W, Zhang Y, Huang Q, Gao W, Qin L, Meng J, Witjes H, Schindler E, Guiastrennec B, Bellanti F, Spellman DS, Roadcap B, Kalinova M, Fok-Seang J, Catchpole AP, Espeseth AS, Stoch SA, Lai E, Vora KA, Aliprantis AO, Sachs JR. Maas BM, et al. EBioMedicine. 2021 Nov;73:103651. doi: 10.1016/j.ebiom.2021.103651. Epub 2021 Nov 11. EBioMedicine. 2021. PMID: 34775220 Free PMC article.
A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK-1654 in healthy Japanese adults.
Orito Y, Otani N, Matsumoto Y, Fujimoto K, Oshima N, Maas BM, Caro L, Aliprantis AO, Cox KS, Tokumaru O, Kodama M, Kudo H, Imai H, Uemura N. Orito Y, et al. Among authors: maas bm. Clin Transl Sci. 2022 Jul;15(7):1753-1763. doi: 10.1111/cts.13290. Epub 2022 May 17. Clin Transl Sci. 2022. PMID: 35506164 Free PMC article. Clinical Trial.
A phase I, randomized, placebo-controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID-19.
Nakamura K, Fujimoto K, Hasegawa C, Aoki I, Yoshitsugu H, Ugai H, Yatsuzuka N, Tanaka Y, Furihata K, Maas BM, Wickremasingha PK, Duncan KE, Iwamoto M, Stoch SA, Uemura N. Nakamura K, et al. Among authors: maas bm. Clin Transl Sci. 2022 Nov;15(11):2697-2708. doi: 10.1111/cts.13395. Epub 2022 Sep 23. Clin Transl Sci. 2022. PMID: 36053806 Free PMC article. Clinical Trial.
Assessment of pharmacokinetics, safety, and tolerability following twice-daily administration of molnupiravir for 10 days in healthy participants.
Iwamoto M, Duncan KE, Wickremasingha PK, Zhao T, Liberti MV, Lemoine L, Decaesteker T, Rottey S, Maas BM, Gillespie G, Stoch SA. Iwamoto M, et al. Among authors: maas bm. Clin Transl Sci. 2023 Oct;16(10):1947-1956. doi: 10.1111/cts.13602. Epub 2023 Aug 8. Clin Transl Sci. 2023. PMID: 37526305 Free PMC article. Clinical Trial.
Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults.
Phuah JY, Maas BM, Tang A, Zhang Y, Caro L, Railkar RA, Swanson MD, Cao Y, Li H, Roadcap B, Catchpole AP, Aliprantis AO, Vora KA. Phuah JY, et al. Among authors: maas bm. Biomed Pharmacother. 2023 Dec 31;169:115851. doi: 10.1016/j.biopha.2023.115851. Epub 2023 Nov 14. Biomed Pharmacother. 2023. PMID: 37976891 Free article.
A Phase 1b/2a Single Ascending Dose Study of a Half-life Extended RSV Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants.
Madhi SA, Simões EAF, Acevedo A, Novoa Pizarro JM, Shepard JS, Railkar RA, Cao X, Maas BM, Zang X, Krick A, Roadcap B, Vora KA, Aliprantis AO, Lee AW, Sinha A. Madhi SA, et al. Among authors: maas bm. J Infect Dis. 2024 Nov 27:jiae581. doi: 10.1093/infdis/jiae581. Online ahead of print. J Infect Dis. 2024. PMID: 39601265
Assessment of pharmacokinetics and tolerability following single-dose administration of molnupiravir in participants with hepatic or renal impairment.
Duncan KE, Carstens RP, Butterfield KL, Jin Y, Inbody LR, Schaeffer AK, Matthews CZ, Zhao T, Patel S, Maas BM, Cheng MH, Stoch SA. Duncan KE, et al. Among authors: maas bm. Clin Transl Sci. 2024 Dec;17(12):e70073. doi: 10.1111/cts.70073. Clin Transl Sci. 2024. PMID: 39601078 Free PMC article. Clinical Trial.
19 results